Clinical Trials Logo
  1. Home
  2. Mesotheliomas Pleural
  3. NCT03760575

Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

Mesotheliomas Pleural Clinical Trial

Official title:
Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

Clinical Trial Summary

The study is a single-arm phase I trial to evaluate the safety, feasibility, and preliminary efficacy of the addition of pembrolizumab and image-guided resection to surgical therapy and chemotherapy for malignant pleural mesothelioma (MPM).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03760575
Study type Interventional
Source Abramson Cancer Center at Penn Medicine
Contact Corey Langer, MD
Phone 2156623914
Email Corey.Langer@uphs.upenn.edu
Status Recruiting
Phase Phase 1
Start date January 10, 2023
Completion date December 31, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05500508 - Oral AMXT 1501 Dicaprate in Combination With IV DFMO Phase 1/Phase 2
Recruiting NCT05304208 - dENdritic Cell Therapy Combined With SURgEry in Mesothelioma Phase 1
Recruiting NCT04400539 - The IMmunotherapy Pleural 5-ALA PDT Phase 2
Active, not recruiting NCT04300244 - Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma Phase 2
Recruiting NCT03475953 - A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors Phase 1/Phase 2
Recruiting NCT05278975 - Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma Phase 1/Phase 2
Recruiting NCT04214015 - A Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma
Recruiting NCT04287829 - Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients Phase 2
Active, not recruiting NCT05451849 - A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer Phase 1/Phase 2
Recruiting NCT04996017 - Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso) Phase 3
Active, not recruiting NCT03054298 - CAR T Cells in Mesothelin Expressing Cancers Phase 1
Recruiting NCT06451536 - Ga-68 FAPI PET Before Immunotherapy N/A
Active, not recruiting NCT03907852 - Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer Phase 1/Phase 2